ArticleHuman vaccines & immunotherapeutics2012
Vaccines against Toxoplasma gondii: status, challenges and future directions.
Article in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Search for Drugs Derived from Natural Products forCurrent topics in medicinal chemistry · 2024Pooled it
- Live-attenuatedVirulence · 2026Article
- Multi-epitope mRNA vaccine and protein vaccine protect mice against Toxoplasma gondii.Parasites & vectors · 2026Article
- Bioinformatics-driven design and protective efficacy assessment of a multi-epitope vaccine forFrontiers in immunology · 2026Article
- Seroprevalence and associated behavioral factors of Toxoplasma gondii infection among pregnant women in Pokhara Valley, Nepal.Tropical medicine and health · 2025Article
- Research on inner membrane complex protein 1: a novel nanovaccines against Toxoplasma gondii.BMC veterinary research · 2025Article
- Review of Toxoplasmosis: What We Still Need to Do.Veterinary sciences · 2025Review
- The Development of TIM-Barrel Based Multi-Epitope Protein forAnimals : an open access journal from MDPI · 2025Article
- MIC13 ofJournal of parasitology research · 2025Article
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- Heterologous immunization targeting the CST1 antigen confers better protection than ROP18 in mice.Nanomedicine (London, England) · 2024Article
- Q fever and toxoplasmosis in South African livestock and wildlife: a retrospective study on seropositivity, sporadic abortion, and stillbirth cases in livestock caused by Coxiella burnetii.BMC veterinary research · 2023Article
- Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Article
- Nano-Encapsulated Antioxidant: Retinoic Acid as a Natural Mucosal Adjuvant for Intranasal Immunization against Chronic Experimental Toxoplasmosis.Tropical medicine and infectious disease · 2023Article
- Toxoplasma gondii vaccine candidates: a concise review.Irish journal of medical science · 2023Review
- Protective mucosal and systemic immunity induced by virus-like particles expressing Toxoplasma gondii cyst wall protein.PloS one · 2023Article
- Mining the Proteome ofAnimals : an open access journal from MDPI · 2022Review
- Nano vaccines forFrontiers in immunology · 2022Article
- Clinical validation of visual LAMP and qLAMP assays for the rapid detection ofFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii is a ubiquitous protozoan parasite that can infect a wide range of animals including humans. This single known species in the genus Toxoplasma is considered as one of the most successful eukaryotic pathogens which is of major medical and veterinary importance. Effective vaccines may contribute toward preventing and controlling the spread of toxoplasmosis. The present communication addresses the current status of development of vaccines against T. gondii. Further discussion is made on the difficulties along with challenges, such as vaccine construct, mode of vaccine administration and standardization of immunization evaluation. Finally suggestions are made on possible directions for future research on the development of vaccines against T. gondii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.